Last reviewed · How we verify

NESP - Novel Erythropoiesis Stimulating Protein

Mirhashemi, Ramin, M.D. · Phase 2 active Small molecule

NESP - Novel Erythropoiesis Stimulating Protein is a Small molecule drug developed by Mirhashemi, Ramin, M.D.. It is currently in Phase 2 development.

At a glance

Generic nameNESP - Novel Erythropoiesis Stimulating Protein
SponsorMirhashemi, Ramin, M.D.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NESP - Novel Erythropoiesis Stimulating Protein

What is NESP - Novel Erythropoiesis Stimulating Protein?

NESP - Novel Erythropoiesis Stimulating Protein is a Small molecule drug developed by Mirhashemi, Ramin, M.D..

Who makes NESP - Novel Erythropoiesis Stimulating Protein?

NESP - Novel Erythropoiesis Stimulating Protein is developed by Mirhashemi, Ramin, M.D. (see full Mirhashemi, Ramin, M.D. pipeline at /company/mirhashemi-ramin-m-d).

What development phase is NESP - Novel Erythropoiesis Stimulating Protein in?

NESP - Novel Erythropoiesis Stimulating Protein is in Phase 2.

Related